Startseite>>Signaling Pathways>> Others>>JH295 hydrate

JH295 hydrate

Katalog-Nr.GC60959

JH295-Hydrat ist ein potenter, irreversibler und selektiver Hemmer der NIMA-verwandten Kinase 2 (Nek2) mit einem IC50 von 770 nM. JH295-Hydrat hemmt zellulÄres Nek2 durch Alkylierung von Cys22. JH295-Hydrat ist gegen die mitotischen Kinasen Cdk1, Aurora B oder Plk1 inaktiv und stÖrt die bipolare Spindelanordnung oder den Spindelanordnungs-Checkpoint nicht.

Products are for research use only. Not for human use. We do not sell to patients.

JH295 hydrate Chemische Struktur

Größe Preis Lagerbestand Menge
1mg
649,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 770 nM. JH295 hydrate inhibits cellular Nek2 via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint[1].

JH295 (Compound 16; 0.08-20 μM; 45 minutes; RPMI7951 cells) treatment inhibits WT Nek2 in cells with an IC50 of ~1.3 μM, whereas it has little effect on the C22V mutant[1]. Western Blot Analysis[1] Cell Line: RPMI7951 cells

[1]. Jeffrey C Henise, et al. Irreversible Nek2 kinase inhibitors with cellular activity. J Med Chem. 2011 Jun 23;54(12):4133-46.

Bewertungen

Review for JH295 hydrate

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for JH295 hydrate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.